Back to top
more

Avanos Medical (AVNS)

(Delayed Data from NYSE)

$24.00 USD

24.00
153,331

+0.46 (1.95%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $23.99 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Insulet (PODD) Benefits From Omnipod 5 Launch, Expansion

by Zacks Equity Research

Insulet (PODD) witnesses continued uptake of Omnipod through the U.S. pharmacy channel.

NextGen's (NXGN) New Cloud-Based Solution to Improve Workflow

by Zacks Equity Research

NextGen's (NXGN) latest product is expected to simplify connectivity for healthcare providers, thereby solving clinical data exchange challenges.

CVS Health (CVS) Nears Completion of $8B SGFY Acquisition

by Zacks Equity Research

According to CVS Health (CVS), Signify Health, a leading healthcare platform, is set to play a critical role in advancing its healthcare services strategy.

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on solid fourth-quarter 2022 performance and its strategies to accelerate growth.

Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Down

by Zacks Equity Research

The U.S. Healthcare segment of Walgreens Boots (WBA) grows on key contract wins, continued partnership growth and a strong focus on execution during fiscal Q2.

Elevance (ELV) Arm to Bring Virtual-First Plans to Georgia

by Zacks Equity Research

The cocktail of virtual and in-person options from Elevance Health's (ELV) part of the Anthem family of brands is expected to enrich members' health experience.

Thermo Fisher (TMO) Opens New Cell Therapy Facility at UCSF

by Zacks Equity Research

Thermo Fisher's (TMO) new cell therapy facility at UCSF is likely to accelerate the development of advanced therapies.

Quest Diagnostics (DGX) Introduces New Post-COVID-19 Panels

by Zacks Equity Research

Quest Diagnostics' (DGX) latest panels provide consumers a deeper look into their health, helping to prepare them for meaningful discussions with their healthcare providers

Walgreens Boots (WBA) Benefits From Innovation Amid Margin Woe

by Zacks Equity Research

Walgreens Boots' (WBA) comparable pharmacy sales decline reflects lower demand for COVID-19 services.

Here's Why You Should Retain Inogen (INGN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Abbott's (ABT) CardioMEMS Favors Heart Failure Management

by Zacks Equity Research

Abbott (ABT) announces key findings from meta-analysis, which shows remote pressure monitoring to be a life-extending option among heart failure patients.

Catalent (CTLT) Inks Deal for Nasal Spray for Opioid Overdoses

by Zacks Equity Research

Catalent's (CTLT) latest commercial supply agreement is expected to combat the opioid epidemic by making OTC naloxone more widely and easily accessible.

Globus Medical (GMED) to Gain From NUVA Deal Amid Rising Costs

by Zacks Equity Research

The NuVasive acquisition aims to outpace market growth by combining Globus Medical's (GMED) engineering and NuVasive's relations, education and training.

Smith & Nephew's (SNN) CIT Technology Favored by New Study

by Zacks Equity Research

Smith & Nephew (SNN) achieves a positive response for its COBLATION-Technology-infused Intracapsular Tonsillectomy Technique, providing fast patient recovery over existing surgeries.

Medtronic (MDT) to Enhance AI Innovation With New Platform

by Zacks Equity Research

Medtronic's (MDT) GI Genius intelligent endoscopy module is the first FDA-cleared, AI-assisted colonoscopy tool to help physicians detect polyps that can lead to colorectal cancer.

3 Reasons to Retain QuidelOrtho (QDEL) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

Quest Diagnostics (DGX) Advances Transplant Testing Service

by Zacks Equity Research

These services by Quest Diagnostics (DGX) are available to recipients and living donors across the United States (excluding Alaska and Hawaii), broadening access for both donor and patient.

Syneos Health (SYNH) Partners With KX for Data-Driven Insights

by Zacks Equity Research

Syneos Health's (SYNH) partnership with KX is likely to accelerate clinical trial execution using AI-enabled solutions.

Here's Why You Should Retain Abbott (ABT) Stock for Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.

Neogen (NEOG) Receives New Label Claims for Viroxide Super

by Zacks Equity Research

Neogen's (NEOG) Viroxide Super active constituents are potassium peroxymonosulfate and sodium chloride, which have been verified effective against multiple industry-relevant bacteria and viruses.

Three Reasons to Add Masimo (MASI) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

Chemed (CHE) Up on Roto-Rooter Sales Growth, Strong Admissions

by Zacks Equity Research

Chemed (CHE) records increases in drain cleaning, plumbing, excavation and water restoration revenues within the Roto-Rooter branch commercial business.

Henry Schein (HSIC) Bolsters Dental Practices With AI Tools

by Zacks Equity Research

Henry Schein (HSIC) integrates AI-enabled solutions, Dentrix Ascend Detect AI and Dentrix Ascend Voice, into its cloud-based dental software.

The Joint (JYNT) to Enter Puerto Rico With New Franchise Deal

by Zacks Equity Research

The Puerto Rico deal with the Comerfords marks The Joint's (JYNT) first franchise deal outside the continental United States.

Is Avanos Medical (AVNS) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.